Hanmi Science
Hanmi Science Co., Ltd., through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally. It develops drugs in the areas of diabetes and anti-cancer, as well as children's and adult's bowel preparation and cold medicines, and cephalosporin antibiotics. The company also offers general foods, health functional foods, soy milk, and medical equipment. In addition… Read more
Hanmi Science (008930) - Net Assets
Latest net assets as of September 2025: ₩921.90 Billion KRW
Based on the latest financial reports, Hanmi Science (008930) has net assets worth ₩921.90 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩1.45 Trillion) and total liabilities (₩524.43 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩921.90 Billion |
| % of Total Assets | 63.74% |
| Annual Growth Rate | 9.7% |
| 5-Year Change | 27.32% |
| 10-Year Change | 43.55% |
| Growth Volatility | 16.43 |
Hanmi Science - Net Assets Trend (2000–2024)
This chart illustrates how Hanmi Science's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Hanmi Science (2000–2024)
The table below shows the annual net assets of Hanmi Science from 2000 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩838.70 Billion | +6.51% |
| 2023-12-31 | ₩787.47 Billion | +8.65% |
| 2022-12-31 | ₩724.75 Billion | +4.99% |
| 2021-12-31 | ₩690.29 Billion | +4.79% |
| 2020-12-31 | ₩658.73 Billion | +2.02% |
| 2019-12-31 | ₩645.69 Billion | -1.13% |
| 2018-12-31 | ₩653.09 Billion | -1.81% |
| 2017-12-31 | ₩665.15 Billion | +2.72% |
| 2016-12-31 | ₩647.56 Billion | +10.84% |
| 2015-12-31 | ₩584.25 Billion | +39.87% |
| 2014-12-31 | ₩417.71 Billion | +2.11% |
| 2013-12-31 | ₩409.07 Billion | +3.85% |
| 2012-12-31 | ₩393.89 Billion | +5.81% |
| 2011-12-31 | ₩372.25 Billion | -38.45% |
| 2010-12-31 | ₩604.83 Billion | +35.95% |
| 2009-12-31 | ₩444.88 Billion | +13.20% |
| 2008-12-31 | ₩393.00 Billion | +12.02% |
| 2007-12-31 | ₩350.82 Billion | +20.49% |
| 2006-12-31 | ₩291.16 Billion | +32.55% |
| 2005-12-31 | ₩219.66 Billion | +20.82% |
| 2004-12-31 | ₩181.81 Billion | +16.83% |
| 2003-12-31 | ₩155.62 Billion | +6.27% |
| 2002-12-31 | ₩146.43 Billion | +11.19% |
| 2001-12-31 | ₩131.69 Billion | +44.82% |
| 2000-12-31 | ₩90.93 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Hanmi Science's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 82226.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩631.25 Billion | 75.07% |
| Other Components | ₩209.67 Billion | 24.93% |
| Total Equity | ₩840.93 Billion | 100.00% |
Hanmi Science Competitors by Market Cap
The table below lists competitors of Hanmi Science ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Guizhou Chitianhua Co Ltd
SHG:600227
|
$673.87 Million |
|
PT Vale Indonesia Tbk
F:XT3B
|
$674.14 Million |
|
Godawari Power And Ispat limited
NSE:GPIL
|
$674.34 Million |
|
u-blox Holding AG
PINK:UBLXF
|
$674.41 Million |
|
SMU S.A
SN:SMU
|
$673.22 Million |
|
Marten Transport Ltd
NASDAQ:MRTN
|
$673.16 Million |
|
SKURF
PINK:SKURF
|
$673.09 Million |
|
Terna Energy Societe Anonyme Commercial Technical Company
PINK:TREAF
|
$672.97 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hanmi Science's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 787,506,950,820 to 840,928,986,270, a change of 53,422,035,450 (6.8%).
- Net income of 59,421,641,040 contributed positively to equity growth.
- Dividend payments of 20,324,103,200 reduced retained earnings.
- Share repurchases of 1,930,477,520 reduced equity.
- Other factors increased equity by 16,254,975,130.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩59.42 Billion | +7.07% |
| Dividends Paid | ₩20.32 Billion | -2.42% |
| Share Repurchases | ₩1.93 Billion | -0.23% |
| Other Changes | ₩16.25 Billion | +1.93% |
| Total Change | ₩- | 6.78% |
Book Value vs Market Value Analysis
This analysis compares Hanmi Science's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.07x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 3.71x to 3.07x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩10280.35 | ₩38150.00 | x |
| 2018-12-31 | ₩10095.47 | ₩38150.00 | x |
| 2019-12-31 | ₩9982.34 | ₩38150.00 | x |
| 2020-12-31 | ₩10185.62 | ₩38150.00 | x |
| 2021-12-31 | ₩10261.19 | ₩38150.00 | x |
| 2022-12-31 | ₩10871.82 | ₩38150.00 | x |
| 2023-12-31 | ₩11583.95 | ₩38150.00 | x |
| 2024-12-31 | ₩12418.89 | ₩38150.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hanmi Science utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.07%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.63%
- • Asset Turnover: 0.95x
- • Equity Multiplier: 1.60x
- Recent ROE (7.07%) is below the historical average (10.97%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 12.09% | 7.10% | 0.61x | 2.81x | ₩1.84 Billion |
| 2001 | 17.44% | 10.75% | 0.66x | 2.45x | ₩9.00 Billion |
| 2002 | 15.98% | 8.46% | 0.83x | 2.29x | ₩7.99 Billion |
| 2003 | 8.40% | 4.43% | 0.81x | 2.34x | ₩-2.24 Billion |
| 2004 | 18.23% | 8.70% | 0.94x | 2.22x | ₩13.54 Billion |
| 2005 | 20.22% | 10.57% | 0.97x | 1.98x | ₩21.15 Billion |
| 2006 | 26.43% | 16.33% | 0.85x | 1.91x | ₩45.13 Billion |
| 2007 | 16.01% | 9.97% | 0.77x | 2.08x | ₩19.89 Billion |
| 2008 | 19.53% | 11.79% | 0.72x | 2.29x | ₩34.92 Billion |
| 2009 | 12.10% | 7.32% | 0.77x | 2.14x | ₩8.77 Billion |
| 2010 | 1.54% | 0.92% | 0.63x | 2.66x | ₩-32.71 Billion |
| 2012 | 3.18% | 61.85% | 0.04x | 1.24x | ₩-26.79 Billion |
| 2013 | 2.35% | 4.35% | 0.38x | 1.42x | ₩-31.21 Billion |
| 2014 | 5.12% | 4.00% | 0.72x | 1.79x | ₩-20.29 Billion |
| 2015 | 30.59% | 22.99% | 0.83x | 1.60x | ₩120.15 Billion |
| 2016 | 1.23% | 1.19% | 0.69x | 1.50x | ₩-56.59 Billion |
| 2017 | 4.52% | 4.61% | 0.69x | 1.41x | ₩-36.45 Billion |
| 2018 | 2.76% | 2.55% | 0.77x | 1.40x | ₩-47.29 Billion |
| 2019 | 4.76% | 3.76% | 0.90x | 1.41x | ₩-33.83 Billion |
| 2020 | 3.43% | 2.64% | 0.93x | 1.40x | ₩-43.27 Billion |
| 2021 | 6.22% | 4.52% | 1.00x | 1.38x | ₩-26.09 Billion |
| 2022 | 9.55% | 6.62% | 0.94x | 1.53x | ₩-3.27 Billion |
| 2023 | 14.62% | 9.23% | 1.02x | 1.56x | ₩36.37 Billion |
| 2024 | 7.07% | 4.63% | 0.95x | 1.60x | ₩-24.67 Billion |
Industry Comparison
This section compares Hanmi Science's net assets metrics with peer companies in the Medical Distribution industry.
No peer company data available for comparison.